Roche antibody shows strong tumor responses in lymphoma study

An The standard bispecific antibody developed by Roche induced high and long-lasting response rates in patients with a slow-growing type of lymphoma – study results likely to gain approval for treatment and help compete with tailor-made CAR-T therapy.

The study included 90 patients, all of whom received intravenous infusions of the drug Roche, called mosunetuzumab. Complete remissions were reported in 54 patients, or 60%, indicating that their disease was undetectable. The overall response rate was 80% with a median duration of response of nearly 23 months.

Unlock this article by subscribing to STAT + and enjoy your first 30 days free!


What is that?

STAT + is STAT’s premium subscription service for in-depth coverage and analysis of biotechnology, pharmaceuticals, policy and life sciences. Our award-winning team covers news on Wall Street, political developments in Washington, early scientific breakthroughs and clinical trial results, as well as healthcare disruptions in Silicon Valley and beyond.

What is included?

  • Daily reporting and analysis
  • Industry’s most comprehensive coverage from a powerful team of journalists
  • Newsletters reserved for subscribers
  • Daily newsletters to keep you informed of the most important industry news of the day
  • STAT + conversations
  • Weekly opportunities to engage with our journalists and leading industry experts in live video chats
  • Exclusive industry events
  • Premium access to subscriber-only networking events nationwide
  • The best reporters in the industry
  • The most reliable and most connected newsroom in the healthcare industry
  • And much more
  • Exclusive interviews with industry leaders, profiles and premium tools, like our CRISPR Trackr.

Source link

Comments are closed.